Poplar Therapeutics
Last verified 2026-06-12. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $50.0Mattributed |
|---|---|
| Latest round | series-a, $50.0M, 2026-01-07attributed |
| Founded | 2024 |
| Headquarters | San Francisco |
| Industry | healthcare |
| Stage | series-a |
| Website | poplartx.com |
Poplar Therapeutics develops pharmaceutical treatments focused on new anti-IgE medicines to help patients manage allergic conditions. Its audience includes patients with anti-IgE-treatable conditions, healthcare professionals, and investors. Its edge is targeting therapies that aim to push beyond the limits of existing anti-IgE treatments.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-01-07 | series-a | $50.0M | undisclosed |
Detected tech stack
astra 4.12.0, cloudflare, cloudflare bot management, doubleclick floodlight, google analytics, google tag manager, gravity forms 2.10.3, gutenberg, http/3, mysql, php, spectra 2.19.17
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $50.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $50.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | poplartx.com, read 2026-06-12 |
| Description | self-reported | poplartx.com, read 2026-06-12 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.